Saturday 17 October 2026
Export IMMX’s income statement to Excel — free account
Immix Biopharma, Inc.
IMMX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 18.2% and free cash flow fell 116.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.98
0.70
−8.06%
Follow IMMX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(182.55%) | (55.00%) | (74.46%) | (34.18%) | |
| (104.21%) | (46.07%) | (60.47%) | (31.34%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(291.17%) | (31.44%) | (41.57%) | (17.60%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.48) | (0.75) | (0.59) | (0.61) | |
Free Cash Flow |
(15.45) | (24.66) | (32.77) | (39.09) | |
Capital Expenditures |
(1.07) | (0.73) | (0.70) | (0.59) | |
| Other line items | |||||
Cash ROIC |
(63.82%) | (12.70%) | (18.73%) | (8.48%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.61 | 0.81 | 0.92 | 0.96 | |
Depreciation/Fixed assets |
0.13 | 0.14 | 0.18 | 0.21 | |
Capex/Depreciation |
(3.41) | (2.01) | (1.60) | (1.21) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.45) | (0.73) | (0.58) | (0.60) | |
Capex per Share |
(0.03) | (0.02) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates